ADVERSE REACTIONS
The following reactions were reported with verapamil hydrochloride injection used in controlled U.S. clinical trials involving 324 patients:
Cardiovascular: Symptomatic hypotension (1.5%); bradycardia (1.2%); severe tachycardia (1.0%). The worldwide experience in open clinical trials in more than 7,900 patients was similar.
Central Nervous System Effects: Dizziness (1.2%); headache (1.2%). Occasional cases of seizures during verapamil injection have been reported.
Gastrointestinal: Nausea (0.9%); abdominal discomfort (0.6%).
In rare cases of hypersensitive patients, broncho/laryngeal spasm accompanied by itch and urticaria has been reported.
The following reactions have been reported at low frequency: emotional depression, rotary nystagmus, sleepiness, vertigo, muscle fatigue, diaphoresis, and respiratory failure.
| |||
| Suggested Treatment of Acute Cardiovascular Adverse Reactions* | |||
| The frequency of these adverse reactions was quite low, and experience with their treatment has been limited. | |||
| Adverse Reaction | Proven Effective Treatment | Supportive Treatment | |
| 1. | Symptomatic hypotension requiring treatment | Dopamine intravenous Calcium chloride intravenous Norepinephrine bitartrate intravenous Metaraminol bitartrate intravenous Isoproterenol HCl intravenous | Intravenous fluids Trendelenburg position |
| 2. | Bradycardia, AV block, Asystole | Isoproterenol HCl intravenous Calcium chloride intravenous Norepinephrine bitartrate intravenous Atropine intravenous Cardiac pacing | Intravenous fluids (slow drip) |
| 3. | Rapid ventricular rate (due to antegrade conduction in flutter/fibrillation with W-P-W or L-G-L syndromes) | DC-cardioversion (high energy may be required) Procainamide intravenous Lidocaine intravenous | Intravenous fluids (slow drip) |